Intuitive’s E-100 generator and SynchroSeal gets the FDA clearance
Category: #health  By Pankaj Singh  Date: 2019-11-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Intuitive’s E-100 generator and SynchroSeal gets the FDA clearance

Intuitive, a US-based developer, manufacturer, and marketer of the robotic products designed to improve clinical results of patients through robot-assisted surgeries, reportedly announced that two of its technologies for its da Vinci surgical systems received FDA clearance.

E-100 generator and SynchroSeal instrument are the two new technologies of the company. E-100 generator is the company’s first internally designed robotic generator to support two crucial instruments on the da Vinci Xi™ and X® systems. The other instrument, SynchroSeal instrument provides improved capabilities in the field of general surgery.    

Senior Vice President and General Manager for Instruments and Accessories, Intuitive, Bob DeSantis stated that the company is thrilled to get the FDA clearance, and offering surgeons an extra tool for the Xi and X da Vinci platforms.

DeSantis further added that the company developed the E-100 generator and SynchroSeal to assist surgeons in quickly sealing and transecting vessels and tissues, enabling an efficient technique.

The E-100 is the company’s first generator and is provided as an upgrade to power SynchroSeal and Vessel Sealer Extend. SynchroSeal would allow a surgeon to perform rapid single-step sealing and transection using a single pedal press.  

SynchroSeal instrument utilizes advanced bipolar energy through its raised cut electrode for tissue transection. It then cools down quickly allowing surgeons to move on to the further step. SynchroSeal provides improved versatility to the Energy portfolio of da Vinci through its rapid sealing cycle, wristed articulation, and refined curved jaw.   

There are multiple models of the Intuitive’s da Vinci surgical system. These systems are built to help surgeons in performing minimally invasive surgery. They provide surgeons a magnified view, high-definition 3D vision, as well as computer and robotic assistance.

These systems utilize specialized instrumentation, which includes wristed instruments such as scissors, forceps and scalpels and a miniaturized surgical camera. These instruments are designed to help surgeons with precise reconstruction and dissection inside the body.

Earlier in July, the company acquired the robotic endoscopic business of Schölly Fiberoptic. The acquisition integrated Schölly’s robotic endoscope production line and two Schölly sites into Intuitive’s business.

 

Source credit: https://www.biospace.com/article/releases/u-s-fda-clears-synchroseal-and-e-100-generator-for-da-vinci-x-xi-platforms/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.